Hereditary Angioedema - C1 Esterase Inhibitors (Subcutaneous)
Customize your policy alerts
Sign up for Cigna Policy IP0316 alerts
Get alerted when Policy IP0316 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity coverage for Haegarda (subcutaneous C1 esterase inhibitor [human]) used for routine prophylaxis of hereditary angioedema due to C1-INH deficiency. It applies to Cigna-administered health benefit plans, subject to the applicable benefit plan document and laws.
The policy added HCPCS code J0599 for injection of human C1 esterase inhibitor (Haegarda), 10 units.
The policy added a requirement that the patient have hereditary angioedema type I or type II confirmed by specified diagnostic criteria.
The policy removed the requirement for a confirmed pathogenic variant in the SERPING1, F12, ANGPT1, PLG, or KNG1 gene.
The policy added a requirement involving a physician who specializes in the treatment of hereditary angioedema or related disorders.
The policy added continuation criteria for patients currently receiving Haegarda prophylaxis.
The policy removed the condition excluding episodes of angioedema with normal C1 inhibitor levels and function that were not related to a documented pathogenic variant in F12, ANGPT1, PLG, or KNG1.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.